Inovio Pharmaceuticals (INO) investor relations material

Executive summary

• INO-3107 for Recurrent Respiratory Papillomatosis (RRP) is under FDA Accelerated Approval review with a PDUFA date of October 30, 2026; mid-cycle review completed with no new significant issues, but eligibility for accelerated approval remains under discussion.

• Commercial launch preparations for INO-3107 are advancing, including market research, pricing strategy, and engagement with the RRP community and key commercial partners.

• Pipeline progress includes partnerships for glioblastoma (INO-5412 with Akeso and Dana-Farber) and preclinical advances in next-generation DNA-encoded protein and antibody programs for rare diseases.

• No product revenues; operations funded by equity offerings, grants, and collaborations.

Financial highlights

• Q1 2026 net loss was $19.7M ($0.28/share), unchanged from Q1 2025, with a 45% improvement in net loss per share due to increased share count.

• Operating expenses for Q1 2026 were $21.9M, down 13% year-over-year, with R&D at $14.1M and G&A at $7.9M.

• Cash, cash equivalents, and short-term investments totaled $37.7M as of March 31, 2026, excluding $16M from an April 2026 equity offering.

• April 2026 public equity offering raised $16M, extending cash runway into Q1 2027.

• No outstanding debt; accumulated deficit reached $1.8B as of March 31, 2026.

Outlook and guidance

• Cash runway, including April 2026 equity raise, is projected to fund operations into Q1 2027, beyond the INO-3107 PDUFA date.

• No additional capital raises included in current runway projections, but further financing will be needed for continued operations and product development.

• Focus remains on INO-3107 approval, commercial launch, ongoing regulatory engagement, and confirmatory trial planning.